Sanofi announces new Sarclisa subcutaneous formulation meets co-primary endpoints in IRAKLIA phase 3 study in multiple myeloma: Paris Friday, January 10, 2025, 15:00 Hrs [IST] Res ...
Some results have been hidden because they may be inaccessible to you